STAR Pharmaceutical

Star Pharmaceutical Holdings Limited is a pharmaceutical company primarily focused on the development, manufacturing, and distribution of a wide range of pharmaceutical products in the People's Republic of China. The company's extensive product portfolio includes antibiotics, cardiovascular medications, and respiratory treatments, which are produced in various forms such as injections, capsules, and tablets. Operating through its key subsidiaries, Hainan Star Pharmaceutical and Fujian Star Pharmaceutical, the company maintains GMP-certified manufacturing facilities to ensure high-quality production. Formerly listed on the Singapore Exchange (SGX), the company was privatized in 2019 by its founder and chairman. Star Pharmaceutical leverages a robust distribution network to supply its products to hospitals and retail pharmacies across the high-growth Chinese healthcare market.